The Latest Breaking News from Myovant Sciences

Gainers

 

The U.S. Food and Drug Administration (FDA) has extended the review period for the supplemental New Drug Application (sNDA) from Pfizer Inc.

The European Commission (EC) has approved Myovant Sciences Ltd's (NYSE:MYOV) Orgovyx (relugolix, 120 mg) for advanced hormone-sensitive prostate cancer.  This approval was supported by data from the Phase 3 HERO study. In the HERO study, Orgovyx met the primary endpoint and achieved sustained testosterone suppression to castrate levels (< 50 ng/dL) through 48…

SVB Leerink has decided to maintain its Market Perform rating of Myovant Sciences (NYSE:MYOV) and lower its price target from $19.00 to $12.00. Shares of Myovant Sciences are trading up 8.08% over the last 24 hours, at $11.23 per share.

Gainers

Myovant Sciences (NYSE:MYOV) brought in sales totaling $54.44 million during Q3 according to data provided by Benzinga Pro. However, earnings decreased 193.85%, resulting in a loss of $63.45 million.

  Myovant Sciences (NYSE:MYOV) reported its Q3 earnings results on Wednesday, January 26, 2022 at 07:00 AM. Here's what investors need to know about the announcement.